HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer-Reference-Cited by-同舟云学术

HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer

Published:2014-12-01 Issue:6 Volume:142 Page:755-766
ISSN:1943-7722
Container-title:American Journal of Clinical Pathology
language:en
Short-container-title:

Author:

Lee Hee Jin¹²,Seo An Na¹,Kim Eun Joo¹,Jang Min Hye¹,Suh Koung Jin³,Ryu Han Suk⁴,Kim Yu Jung⁵⁶,Kim Jee Hyun⁵⁶,Im Seock-Ah³⁶,Gong Gyungyub²,Jung Kyung Hae⁷,Park In Ae⁴⁸,Park So Yeon¹⁸

Affiliation:

1. Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, South Korea

2. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

3. Department of Medical Oncology, Seoul National University Hospital, Seoul, South Korea

4. Department of Pathology, Seoul National University Hospital, Seoul, South Korea

5. Department of Medical Oncology, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, South Korea

6. Department of Medical Oncology, Seoul National University College of Medicine, Seoul, South Korea

7. Department of Medical Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

8. Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Link

http://academic.oup.com/ajcp/article-pdf/142/6/755/24999505/ajcpath142-0755.pdf

Reference32 articles.

1. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

2. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease;Press;Cancer Res,1993

3. HER-2/neu oncogene protein and prognosis in breast cancer;Tandon;J Clin Oncol,1989

4. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease;Cobleigh;J Clin Oncol,1999

5. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of HER2-targeted PET/CT imaging in patients with breast cancer and therapeutic response monitoring;The Oncologist;2024-07-31

2. Discovery of a novel hybrid coumarin-hydroxamate conjugate targeting the HDAC1-Sp1-FOSL2 signaling axis for breast cancer therapy;Cell Communication and Signaling;2024-07-15

3. Combined transcriptome and proteome analysis reveals MSN and ARFIP2 as biomarkers for trastuzumab resistance of breast cancer;Breast Cancer Research and Treatment;2024-05-15

4. Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy;Biomedicines;2024-05-14

5. Bispecific radioimmunoconjugates exploit receptor heterogeneity for positron emission tomography of tumors expressing HER2 and/or EGFR;iScience;2024-05